Skip to main content
. 2017 Mar 27;38(7):998–1008. doi: 10.1038/aps.2016.175

Figure 2.

Figure 2

Cytotoxicity of FFAs and AS-IV on hepatocytes. HepG2 cells or primary murine hepatocytes were treated with various concentrations of FFAs, AS-IV or their combination for 24 h and analyzed using a CCK-8 assay. (A) Cell viability of HepG2 cells exposed to FFAs (0.25–2 mmol/L). (B) Cell viability of HepG2 cells treated with AS-IV (50–400 μg/mL). (C) Cell viability of HepG2 cells co-treated with FFAs (1 mmol/L) and AS-IV (50–200 μg/mL). (D) Cell viability of primary murine hepatocytes exposed to FFAs (0.25–2 mmol/L). (E) Cell viability of primary murine hepatocytes treated with AS-IV (50–400 μg/mL). (F) Cell viability of primary murine hepatocytes co-treated with FFAs (1 mmol/L) and AS-IV (50–200 μg/mL). Data are presented as the mean±SEM of three independent experiments (n=3). *P<0.05, **P<0.01 compared with the control group. FFAs, free fatty acids; AS-IV, astragaloside IV.